ARRIVENT BIOPHARMA, INC.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Dec 2022 | — | $-85.1M | $163.4M |
| Mar 2023 | — | $-97.1M | $191.5M |
| Jun 2023 | — | $-118.5M | $157.8M |
| Sep 2023 | — | $-132.6M | $141.4M |
| Dec 2023 | — | $-153.2M | $150.4M |
| Mar 2024 | — | $317.7M | $317.4M |
| Jun 2024 | — | $296.7M | $298.7M |
| Sep 2024 | — | $277.5M | $282.9M |
| Dec 2024 | — | $257.7M | $74.3M |
| Mar 2025 | — | $202.5M | $49.9M |
| Jun 2025 | — | $249.9M | $112.8M |
| Sep 2025 | — | $305.0M | $112.7M |
| Dec 2025 | — | $307.2M | $45.5M |
| Mar 2026 | — | $324.0M | $62.1M |
| Jun 2026 | — | $366.8M | $154.7M |